Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedersandoz.com
https://www.sandoz.com/rss/feeds/news/media-releases.xml
Get the latest updates from https://www.sandoz.com/rss/feeds/news/media-releases.xml directly as they happen.
Follow now 64 followers
Latest posts
Last updated over 2 years ago
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
over 2 years ago
Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
over 2 years ago
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics...
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
over 2 years ago
Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +5% cc1...
HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis*
over 2 years ago
Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3Additional 196 pack...
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
over 2 years ago
Submission supported by comprehensive analytical and clinical data from new Phase I...
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
over 2 years ago
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare...
Sandoz appoints new Board representative to global AMR Industry Alliance
over 2 years ago
Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to...
Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
over 2 years ago
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease...
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
over 2 years ago
Ad hoc announcement pursuant to Art. 53 LRQ1 sales grew +5% (cc1...
Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio
over 2 years ago
Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure...
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
over 2 years ago
Extending existing master services agreement with Ares Genetics, to develop digital platform...
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
almost 3 years ago
Sandoz gains significant capabilities and assets in medical and drug device development...